The study is recruiting to plan, with 1,277 patients recruited as of 30 May 2018. The incidence of
the various diseases among study participants has been as expected which should ensure the
study generates statistically strong results. Independent quality assurance of the cough audio
recordings has been performed on-site weekly, as per the study protocol, with a sample of the
audio recordings also being reviewed directly by ResApp. Only approximately 1% of recordings
have been found in the quality assurance process to be unacceptable.
- Forums
- ASX - By Stock
- RAP
- Ann: ResApp Provides SMARTCOUGH-C-2 Study Update
Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-2
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online